Birgit C. Schultes - 05 Jan 2026 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: EVP, Chief Scientific Officer
Signature: James Basta, attorney-in-fact
Issuer symbol: NTLA
Transactions as of: 05 Jan 2026
Net transactions value: -$78,359
Form type: 4
Filing time: 07 Jan 2026, 16:05:16 UTC
Previous filing: 03 Oct 2025
Next filing: 03 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Schultes Birgit C	EVP, Chief Scientific Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE	James Basta, attorney-in-fact	07 Jan 2026	0002051419

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Sale	$78,359	-8,508	-7.9%	$9.21	98,533	05 Jan 2026	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.
F2	Includes 925 and 932 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.